94 results on '"Caravatti G"'
Search Results
2. ACE and LRPAP1 Insertion-Deletion Polymorphisms in a Northern Ivory Coast Population
3. COL1A2 gene deletion polymorphism in an Italian and an Ivorian populations
4. Towards a rational approach in the finding of potent peptide ligands for Grb2 SH2
5. Targeting a hydrophobic patch on the surface of the Grb2-SH2 domain leads to high-affinity phosphotyrosine-containing peptide ligands
6. Erythrocyte polymorphisms in five ethnic groups of Northern Côte dʼIvoire
7. Pyrrolo[2,3-d]pyrimidine and Pyrazolo[3,4-d]pyrimidine Derivatives as Selective Inhibitors of the EGF Receptor Tyrosine Kinase
8. Differential inhibition of human secretory and cytosolic phospholipase A2
9. Towards a rational approach in the finding of potent peptide ligands for Grb2 SH2
10. Targeting a hydrophobic patch on the surface of the Grb2-SH2 domain leads to high-affinity phosphotyrosine-containing peptide ligands
11. Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison
12. ChemInform Abstract: Phenylamino-pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC)
13. ChemInform Abstract: Structure-Based Design of Peptidomimetic Ligands of the Grb2-SH2 Domain.
14. A derivative of staurosporine (CGP 41:251) shows selectivity for PKC inhibition andin vitro antiproliferative effects as well asin vivo antitumor activity.Int. J. Cancer,43, 851-866 (1989)
15. In vitro trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors
16. Synthesis and biological evaluation of highly potent analogues of epothilones B and D
17. Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 1
18. Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 2
19. Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility.
20. Highly Potent Inhibitors of the Grb2-SH2 Domain
21. Structure-based design of a non-peptidic antagonist of the SH2 domain of GRB2
22. Structure-based design of peptidomimetic ligands of the Grb2-SH2 domain
23. Potent Antagonists of the SH2 Domain of Grb2: Optimization of the X<INF>+1</INF> Position of 3-Amino-Z-Tyr(PO<INF>3</INF>H<INF>2</INF>)-X<INF>+1</INF>-Asn-NH<INF>2</INF>
24. Structure-Based Design and Synthesis of High Affinity Tripeptide Ligands of the Grb2-SH2 Domain
25. Discovery of 3-Aminobenzyloxycarbonyl as an N-Terminal Group Conferring High Affinity to the Minimal Phosphopeptide Sequence Recognized by the Grb2-SH2 Domain
26. Convergent synthesis of potent peptide inhibitors of the Grb2-SH2 domain by palladium catalyzed coupling of a terminal alkyne
27. ChemInform Abstract: On the Stereochemistry of E′‐ and E′′‐Reactions.
28. ChemInform Abstract: BIOMIMETIC TOTAL SYNTHESIS OF (-)-CODEINE
29. A derivative of staurosporine (CGP 41:251) shows selectivity for PKC inhibition and in vitro antiproliferative effects as well as in vivo antitumor activity. Int. J. Cancer, 43, 851-866 (1989).
30. ChemInform Abstract: Structure-Based Design of Peptidomimetic Ligands of the Grb2-SH2 Domain.
31. ChemInform Abstract: Phenylamino-pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC).
32. A derivative of staurosporine (CGP 41:251) shows selectivity for PKC inhibition and <TOGGLE>in vitro</TOGGLE> antiproliferative effects as well as <TOGGLE>in vivo</TOGGLE> antitumor activity. <TOGGLE>Int. J. Cancer,</TOGGLE> 43, 851866 (1989)
33. Inhibitory activity and selectivity of staurosporine derivatives towards protein kinase C
34. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells
35. Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.
36. Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy.
37. Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.
38. Increasing metabolic stability via the deuterium kinetic isotope effect: An example from a proline-amide-urea aminothiazole series of phosphatidylinositol-3 kinase alpha inhibitors.
39. Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.
40. Identification and optimisation of a 4',5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitors.
41. Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors.
42. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.
43. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.
44. COL1A2 gene deletion polymorphism in an Italian and an Ivorian populations.
45. Entry into a new class of protein kinase inhibitors by pseudo ring design.
46. Hypoxia modulation and radiosensitization by the novel dual EGFR and VEGFR inhibitor AEE788 in spontaneous and related allograft tumor models.
47. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
48. Structure-activity relationships in side-chain-modified epothilone analogues--how important is the position of the nitrogen atom?
49. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
50. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.